Display options
Cite
Chen J, Xu L, Huang C. DHEA inhibits vascular remodeling following arterial injury: a possible role in suppression of inflammation and oxidative stress derived from vascular smooth muscle cells. Mol Cell Biochem. 2013;388(1):75-84doi: 10.1007/s11010-013-1900-7.
Chen, J., Xu, L., & Huang, C. (2014). DHEA inhibits vascular remodeling following arterial injury: a possible role in suppression of inflammation and oxidative stress derived from vascular smooth muscle cells. Molecular and cellular biochemistry, 388(1), 75-84. https://doi.org/10.1007/s11010-013-1900-7
Chen, Jiangbin, et al. "DHEA inhibits vascular remodeling following arterial injury: a possible role in suppression of inflammation and oxidative stress derived from vascular smooth muscle cells." Molecular and cellular biochemistry vol. 388,1 (2014): 75-84. doi: https://doi.org/10.1007/s11010-013-1900-7
Chen J, Xu L, Huang C. DHEA inhibits vascular remodeling following arterial injury: a possible role in suppression of inflammation and oxidative stress derived from vascular smooth muscle cells. Mol Cell Biochem. 2014 Mar;388(1):75-84. doi: 10.1007/s11010-013-1900-7. Epub 2013 Nov 28. PMID: 24287563.
Copy Download .nbib Format: NLM
Share it on

Mol Cell Biochem. 2014 Mar;388(1):75-84. doi: 10.1007/s11010-013-1900-7. Epub 2013 Nov 28.

DHEA inhibits vascular remodeling following arterial injury: a possible role in suppression of inflammation and oxidative stress derived from vascular smooth muscle cells.

Molecular and cellular biochemistry

Jiangbin Chen, Lin Xu, Congxin Huang

Affiliations

  1. Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, People's Republic of China.

PMID: 24287563 DOI: 10.1007/s11010-013-1900-7

Abstract

Vascular remodeling is characterized by the aggregation of vascular smooth muscle cells (VSMCs) in intima. Previous studies have demonstrated that dehydroepiandrosterone (DHEA), a steroid hormone, can reverse vascular remodeling. However, it is still far clear that whether and how DHEA participates in the modulation of VSMCs activation and vascular remodeling. VSMCs were obtained from the thoracic aorta of SD rats. Cell proliferation was evaluated by CCK-8 assay and BrdU assay. To measure VSMCs migration activity, a transwell chamber assay was performed. Quantitative real-time RT-PCR and western blot were used to explore the molecular mechanisms. ROS generation by VSMCs was measured by DCF fluorescence. NADPH oxidase activity and SOD activity were measured by the corresponding kits. NF-κB activity was detected by NF-κB luciferase reporter gene assay. A rat carotid artery balloon injury model was built to evaluate the neointimal formation, and plasma PGF2 was measured by ELISA. Our results showed that DHEA significantly inhibited VSMCs proliferation after angiotensin (Ang II) stimulation by down-regulation of NADPH oxidase activity and ERK1/2 phosphorylation. Ang II can increase IL-6 and MCP-1 expression, but DHEA reverses these changes via inhibiting p38-MAPK/NF-κB (p65) signaling pathway. DHEA has no significant effects on VSMCs phenotype transition, but can reduce the neointimal to media area ratio after balloon injury. DHEA can alleviate oxidative stress and inflammation in VSMCs via ERK1/2 and NF-κB signaling pathway, but has no effect on VSMCs phenotype transition. Furthermore, DHEA attenuates VSMCs activation and neointimal formation after carotid injury in vivo. Taken together, DHEA might be a promising treatment for vascular injury under pathological condition.

References

  1. Mol Cell Biochem. 2010 Jul;340(1-2):55-62 - PubMed
  2. Atherosclerosis. 2009 Sep;206(1):77-85 - PubMed
  3. Arterioscler Thromb Vasc Biol. 1996 Jul;16(7):857-63 - PubMed
  4. J Biol Chem. 2005 May 20;280(20):19966-76 - PubMed
  5. Eur J Heart Fail. 2010 Sep;12(9):966-73 - PubMed
  6. J Biol Chem. 2007 Sep 14;282(37):27229-27238 - PubMed
  7. J Physiol. 2011 May 15;589(Pt 10):2585-96 - PubMed
  8. Clin Chem. 2008 Jan;54(1):24-38 - PubMed
  9. Int J Cardiol. 2012 Jan 26;154(2):147-52 - PubMed
  10. Anticancer Res. 2006 Sep-Oct;26(5A):3205-15 - PubMed
  11. Cardiovasc Res. 2012 Jul 15;95(2):241-50 - PubMed
  12. Circulation. 1992 Nov;86(5):1529-35 - PubMed
  13. Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):1094-100 - PubMed
  14. Physiol Rev. 2006 Apr;86(2):515-81 - PubMed
  15. Am J Physiol Cell Physiol. 2006 Jul;291(1):C50-8 - PubMed
  16. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9488-93 - PubMed
  17. Eur Heart J. 2000 Jun;21(11):890-4 - PubMed
  18. Circulation. 1995 Mar 15;91(6):1757-60 - PubMed
  19. Sci Signal. 2008 Jan 08;1(1):pe1 - PubMed
  20. Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):782-92 - PubMed
  21. Cardiovasc Res. 2004 Mar 1;61(4):671-82 - PubMed
  22. Mol Cell Biochem. 2011 Sep;355(1-2):127-34 - PubMed
  23. Postgrad Med J. 2003 Apr;79(930):195-199; quiz 198-200 - PubMed
  24. Circ Res. 2008 Dec 5;103(12):1370-82 - PubMed
  25. Hypertension. 2003 Apr;41(4):882-90 - PubMed
  26. Am J Physiol Heart Circ Physiol. 2001 Dec;281(6):H2337-65 - PubMed
  27. Am J Physiol Heart Circ Physiol. 2012 Jun 1;302(11):H2148-65 - PubMed
  28. Cardiovasc Res. 2010 May 1;86(2):211-8 - PubMed
  29. Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2592-601 - PubMed
  30. Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):15-26 - PubMed
  31. Cardiovasc Res. 2010 May 1;86(2):254-64 - PubMed
  32. Circulation. 2000 Sep 26;102(13):1470-2 - PubMed
  33. J Trace Elem Med Biol. 2011 Jul;25(3):154-9 - PubMed
  34. Am J Epidemiol. 2001 Jan 1;153(1):79-89 - PubMed
  35. Circulation. 2003 Sep 9;108(10):1246-52 - PubMed
  36. J Immunol. 2007 Nov 15;179(10):7101-9 - PubMed
  37. Biochem Biophys Res Commun. 2010 May 28;396(2):489-94 - PubMed
  38. Atherosclerosis. 2012 Oct;224(2):332-9 - PubMed
  39. J Endocrinol Invest. 2003 Mar;26(3):236-43 - PubMed
  40. J Pharmacol Exp Ther. 2010 Jan;332(1):116-24 - PubMed
  41. Eur J Heart Fail. 2002 Dec;4(6):673-80 - PubMed
  42. J Biol Chem. 2001 Mar 16;276(11):7957-62 - PubMed

Substances

MeSH terms

Publication Types